

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of New Mexico may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSNM has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Preventive Services Policy

Policy Number: CPCP006

Version: 1.0

Enterprise Clinical Payment and Coding Policy Committee Approval Date: January 22, 2025

Effective Date: February 1, 2025

Definitions

The following acronyms have been utilized throughout this reimbursement policy.

ACIP:	Advisory Committee on Immunization
	Practices
CDC:	Centers for Disease Control and Prevention
FDA:	United States Food and Drug Administration
HRSA:	Health Resources and Services
	Administration
PPACA:	Patient Protection and Affordable Care Act of
	2010
USPSTF:	United States Preventive Services Task Force

Description

Section 2713 of the Patient Protection and Affordable Care Act mandates that private health plans provide coverage of preventive services issued by the following agencies: The United States Preventive Services Task Force , the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention , and the Health Resources and Service Administration with respect to women's guidelines and guidelines for infants, children, and adolescents. These services are available at no cost-share when obtained by a member covered under a non-grandfathered plan. This applies to members belonging to individual, small group, large group, and self-insured plans. There is no copay, deductible or coinsurance, even if the individual or family deductible or out-of-pocket maximum has not been met as long as the member utilizes a provider in the plan's network.

Preventive care or preventive medicine refers to measures or services taken to promote health and early detection/prevention of disease(s) and injuries rather than treating them and/or curing them. Preventive care may include, but are not limited to, examinations and screening tests tailored to an individual's age, health, and family history. PPACA does not mandate that preventive services be covered at no member cost-share when obtained out-of-network. Members that obtain preventive services out of their network will be subject to copay, deductible, and coinsurance.

Grandfathered plans are plans that have been in existence prior to March 23, 2010 and are exempt from the requirement of providing preventive services at no member cost share. Grandfathered plans have the opportunity to elect providing coverage of preventive services at no member cost share but are not required to do so.

The USPSTF applies a letter grade for each of the recommendations that are released. The grade definitions for USPSTF recommendations released after July 2012 are as follows https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions

Following the recommendation of the USPTF coverage of Grade "A" and "B" recommendations is provided at no member cost share for members with a nongrandfathered health plan. The USPTF published recommendations can be found at <u>https://www.uspreventiveservicestaskforce.org/BrowseRec/Index</u>

Grade	Definition
Α	The USPSTF recommends the service. There is high
	certainty that the net benefit is substantial.
B	The USPSTF recommends the service. There is high
	certainty that the net benefit is moderate or there
	is moderate certainty that the net benefit is
	moderate to substantial.
C	The USPSTF recommends selectively offering or
C	providing this service to individual patients based
	on professional judgment and patient preferences.
	There is at least moderate certainty that the net
	benefit is small.
D	The USPSTF recommends against the service.
	There is moderate or high certainty that the service
	has no net benefit or that the harms outweigh the
	benefits.
	The USPSTF concludes that the current evidence is
	insufficient to assess the balance of benefits and
	harms of the service. Evidence is lacking, of poor

quality, or conflicting, and the balance of benefits and harms cannot be determined.

The ACIP publishes recommendations on the safe utilization of vaccines. ACIP's recommendations include immunization schedules for children and adolescents as well as adults which can be found at https://www.cdc.gov/vaccines/schedules/hcp/index.html . Travel Immunizations such as, but not limited to, Japanese Encephalitis, Typhoid, Yellow Fever, and Small Pox are excluded from Preventive

Service coverage. Other excluded vaccinations include Anthrax, Bacille Calmette Guerin for Tuberculosis (BCG), and Rabies which are not required by PPACA. Immunizations should be administered in accordance with the ACIP Recommended Child and Adult Immunization Schedules or in accordance with state law or regulations.

HRSA releases Women's Preventive Services guidelines that are aimed at improving women's health by recommending certain preventive services that should be obtained in the clinical setting. HRSA's list of recommendations can be obtained at <u>https://www.hrsa.gov/womensguidelines2016/index.html</u>

HRSA endorses preventive guidelines established by the American Academy of Pediatrics for the health and well-being of infants, children, and adolescents. These recommendations are referred to as Bright Futures and the comprehensive list of Bright Future's recommendations can be found at <u>https://www.hrsa.gov/womens-guidelines</u>

Reimbursement Information

Certain preventive care services may be considered eligible for coverage under the member's benefit plan as required by PPACA and/or an applicable state mandate. In general, these services include, but are not limited to, screenings, immunizations, and other types of care as recommended by the United States Federal Government.

These services are not subject to application of cost-sharing such as co-payments, coinsurance or deductibles when they are considered eligible for coverage and are provided by a network provider. In order for preventive claims to process at the preventive level with no member cost share, the claim must include a preventive diagnosis code, a preventive procedure code, meet medical policy review criteria, and fall within the guidelines issued by the USPSTF, ACIP, HRSA, or Bright Futures. Health care providers (facilities, physicians and other health care professionals) are expected to exercise independent medical judgement in providing care to patients. This Preventive Services Reimbursement policy is not intended to impact care decisions or medical practice.

The following grid provides a list of the recommendations released by the USPSTF, ACIP, HRSA, or Bright Futures along with the corresponding procedure codes and diagnosis codes deemed to be preventive.

USPSTF Recommendations:		
Service:	Procedure	Additional Reimbursement
	Code(s):	Criteria:
Abdominal Aortic Aneurysm	76706	Procedure code 76706 is
Screening		reimbursable as preventive
		when submitted with one of
USPSTF "B" Recommendation		the following: Z13.6,
December 2019		Z87.891, Z72.0, Z00.00,
The USPSTF recommends 1-time		Z00.01, F17.210, F17.200
screening for abdominal aortic		
aneurysm with ultrasonography in		
men aged 65 to 75 years who have		
ever smoked.		
Unhealthy Alcohol Use in	99385, 99386,	Payable with a diagnosis
Adolescents and	99387, 99395,	code in Diagnosis List 1.
Adults: Screening and Behavioral	99396, 99397,	
Counseling	99408, 99409,	
Interventions	G0396, G0397,	
	G0442, G0443	
USPSTF "B" Recommendation		
November 2018		
The USPSTF recommends screening		
for unhealthy alcohol use in primary		
care settings for adults 18 years or		
older, including pregnant women,		
and providing persons engaged in		
risky or hazardous drinking with brief		

behavioral counseling interventions		
to reduce unhealthy alcohol use.		
Anxiety Screening Disorders in	96127, 99384,	Procedure code 96127 is
Adults	99385, 99386,	only reimbursable at the
	99387, 99394,	preventive level when billed
USPSTF Released FINAL "B"	99395, 99396,	with a diagnosis of Z00.129,
Recommendation for Screening for	99397, G0444	Z13.31, Z13.32, Z13.39,
Anxiety Disorders in Adults		Z13.41, or Z13.42
06/30/2023		
The USPSTF recommends screening		
for anxiety disorders in adults,		
including pregnant and postpartum		
persons. Aspirin Use to Prevent		For details about pharmacy
Preeclampsia and Related		benefit coverage, contact
Morbidity and Mortality:		the number on the patient's
Preventive		BCBS member card. A
Medication		patient's pharmacy benefit
		may be managed by a
USPSTF "B" Recommendation		company other than BCBS.
September 2021		
The USPSTF recommends the use of		Coverage includes generic
low-dose aspirin (81 mg/day) as		aspirin 81 mg tablets with a
preventive medication after 12		prescription.
weeks of gestation in persons who		
are at high risk for preeclampsia.		
Asymptomatic Bacteriuria in	81007, 87086,	Payable with a Pregnancy
Adults Screening	87088	Diagnosis
USPSTF "B" Recommendation		
September 2019		
The USPSTF recommends screening		
for asymptomatic bacteriuria using		
urine culture in pregnant persons.		

BRCA-Related Cancer Risk	81212, 81215,	These services are subject to
Assessment,	81216, 81217,	Medical Policy and prior
Genetic Testing	81162, 81163,	authorization may be
	81164, 81165,	required. Procedure codes
USPSTF "B" Recommendation August	81166, 81167,	81212, 81215-81217, 81162-
2019	96040, 99385,	81167, 81307 and 81308 are
USPSTF recommends that primary	99386, 99387,	reimbursable as preventive
care clinicians assess women with a	99395, 99396,	when submitted with one of
personal or family history of breast,	99397, 99401,	the following primary
ovarian, tubal, or peritoneal cancer	99402, 99403,	diagnosis codes:
or who have an ancestry associated	99404, G0463,	Z80.3, Z80.41, Z85.3, Z85.43
with breast cancer susceptibility 1	S0265, 81307,	
and 2 (BRCA1/2) gene mutations with	81308	Procedure code 96040 is
an appropriate brief familial risk		reimbursable as preventive
assessment tool. Women with a		when submitted with one of
positive result on the risk		the following primary
assessment tool should receive		diagnosis codes: Z80.3 or
genetic counseling and, if indicated		Z80.41
after counseling, genetic testing.		
		All other procedure codes
		for BRCA are payable with a
		diagnosis in Diagnosis List 1
Breast Cancer Medications for Risk		For details about pharmacy
Reduction		benefit coverage, contact
		the number on the patient's
USPSTF "B" Recommendations		BCBS member card. A
September 2019		patient's pharmacy benefit
The USPSTF recommends that		may be managed by a
clinicians offer to prescribe risk-		company other than BCBS.
reducing medications, such as		
tamoxifen, raloxifene, or aromatase		Coverage includes generic
inhibitors, to women who are at		anastrozole 1 mg, raloxifene
increased risk for breast cancer and		hcl 60 mg, and tamoxifen
at low risk for adverse medication		citrate 10 and 20 mg tablets
effects.		when used for prevention in
		members ages 35 and over
		with a prescription.

Breast Cancer Screening	77061, 77062,	Payable with a diagnosis
	77063, 77067	code in Diagnosis List 1
USPSTF "B" Recommendation		
January 2016		
The USPSTF recommends biennial		
screening mammography for women		
aged 40-to 74 years.		
<i>Refer</i> also to HRSA's 'Breast Cancer		
Screening for Women at Average		
Risk' recommendation.		
Breastfeeding Primary Care	99401, 99402,	Electric breast pumps
Interventions	99403, 99404,	limited to one per benefit
	99411, 99412,	period. Hospital Grade
USPSTF "B" Recommendation	99347, 99348,	breast pumps are limited to
October 2016	99349, 99350,	rental only.
The USPSTF recommends providing	98960, 98961,	
interventions during pregnancy and	98962. G0513,	Additional reimbursement
after birth to support breastfeeding.	G0514	information available within
		the "Breastfeeding
Refer also to HRSA's 'Breastfeeding	A4281, A4282,	Equipment and Supplies"
Services and Supplies'	A4283, A4284,	
recommendation	A4285, A4286,	G0513 & G0514 are payable
	E0602, E0603,	with a diagnosis code in
	E0604, S9443,	Diagnosis List 1
	A4287	
		Non-physician provider
		types such as Certified
		Lactation Counselors and
		International Board-Certified
		Lactation Consultants will
		only be eligible for
		reimbursement for the
		following codes: S9443,
		98960, 98961, 98962.

Cervical Cancer Screening	99385, 99386,	Payable with a diagnosis
5	99387, 99395,	code in Diagnosis List 1
USPSTF "A" Recommendation August	99396,99397	
2018	,	
The USPSTF recommends screening	G0101, 88141,	
for cervical cancer every 3 years with	88142, 88143,	
cervical cytology alone in women	88147, 88148,	
aged 21 to 29 years. For women aged	88150, 88152,	
30 to 65 years, the USPSTF	88153, 88155,	
recommends screening every 3 years	88164, 88165,	
with cervical cytology alone, every 5	88166, 88167,	
years with high-risk human	88174, 88175,	
papillomavirus (hrHPV) testing alone,	G0123, G0124,	
or every 5 years with hrHPV testing	G0141, G0143,	
in combination with cytology	G0144, G0145,	
(cotesting).	G0147, G0148,	
	P3000, P3001,	
Refer also to HRSA's 'Cervical Cancer	Q0091, 87623,	
Screening' recommendation.	87624, 87625,	
	S0610, S0612,	
	0500T,0096U,	
Chlamydia Screening	86631, 86632,	Payable with a diagnosis
	87110, 87270,	code in Diagnosis List 1
USPSTF "B" Recommendations	87320, 87490,	
September 2021	87491, 87492,	
The USPSTF recommends screening	87801, 87810	
for chlamydia in sexually active		
women age 24 years and younger		
and in women 25 years or older who		
are at increased risk for infection.		

Colorectal Cancer Screening	82270, 82274,	Certain colorectal cancer
	G0328, 44388,	screening services may be
USPSTF "A" Recommendation May	44389,44392,	subject to medical policy
2021	44394, 44401,	criteria and may require
The USPSTF recommends screening	44404,	prior authorization.
for colorectal cancer in all adults	45378,45380,	
aged 50 to 75 years.	45381,45384,	Modifier 33 or PT may be
	45385,45388,	applied
USPSTF "B" Recommendation May	G0105, G0121,	
2021	45330, 45331,	Payable with a diagnosis in
The USPSTF recommends screening	45333,45335,	Diagnosis List 1.
for colorectal cancer in adults aged	45338,45346,	
45 to 49 years.	74263, 88304,	In the instance that a polyp
The risks and benefits of different	88305, G0104,	is removed during a
screening methods vary.	99202, 99203,	preventive colonoscopy, the
	99204, 99205,	colonoscopy as well as the
	99211, 99212,	removal of the polyp and
	99213, 99214,	the labs and services related
	99215, 99417,	to the colonoscopy are
	S0285, 00812,	reimbursable at the
	00813, 81528	preventive level.
		Sedation procedure codes
		99152, 99153, 99156, 99157,
		and G0500 will process at
		the preventive level when
		billed with a diagnosis of
		Z12.11 or Z12.12.
		Procedure code 74263 is
		reimbursable at the
		preventive level when billed
		with one of the following
		three diagnosis codes:
		Z00.00, Z12.11, Z12.12.
		·····

		Procedure code 81528 is reimbursable at the preventive level when billed with Z12.11 or Z12.12 for out of network claims.
		For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.
		Coverage includes generic peg 3350-kcl-na bicarb-nacl- na sulfate, peg 3350-kcl- nacl-na sulfate-na ascorbate-c, or peg 3350- kcl-sod bicarb-nacl solutions for members ages 45 and over with a prescription.
		Diagnosis codes R19.5, K63.5, Z86.0100, Z86.0101, Z86.0102, Z86.0109 will pay at the preventive level.
Congenital Hypothyroidism	84443, 99381,	
Screening	S3620	
USPSTF "A" Recommendation March 2008 The USPSTF recommends screening for congenital hypothyroidism in newborns.		

Dental Caries in Children from	99188	For details about pharmacy
Birth Through Age 5 Years	55100	benefit coverage, contact
Screening		the number on the patient's
Screening		BCBS member card. A
USPSTF "B" Recommendation		
		patient's pharmacy benefit
December 2021		may be managed by a
The USPSTF recommends that		company other than BCBS.
primary care clinicians prescribe oral		
fluoride supplementation starting at		Prescription required for
age 6 months for children whose		both OTC and prescription
water supply is deficient in fluoride.		medications.
USPSTF "B" Recommendation		
December 2021		
The USPSTF recommends that		
primary care clinicians apply fluoride		
varnish to the primary teeth of all		
infants and children starting at the		
age of primary tooth eruption.		
Depression Screening Adults	99385, 99386,	Payable with a diagnosis
	99387, 99395,	code in
USPSTF "B" Recommendation	99396, 99397,	Diagnosis List 1
January 2016	96160, 96161,	
The USPSTF recommends screening	G0444, 96127	Procedure code 96127 is
for depression in the general adult		only reimbursable at the
population, including pregnant and		preventive level when billed
postpartum women. Screening		with a diagnosis of Z00.129,
should be implemented with		Z13.31, Z13.32, Z13.39,
adequate systems in place to ensure		Z13.41, or Z13.42
accurate diagnosis, effective		
treatment, and appropriate follow-		
up.		
USPSTF Released FINAL "B"		
Recommendation for Screening for		
Depression and Suicide Risk in Adults		
Suicide Risk is an "l"		

recommendation which does not apply to the CPCP.		
Depression in Children and	99384, 99385,	Payable with a diagnosis in
Adolescents Screening	99394, 99395, 96127, G0444	Diagnosis List 1 Procedure code 96127 is only
USPSTF "B" Recommendation		reimbursable at the
February 2016		preventive level when billed
The USPSTF recommends screening		with a diagnosis of Z00.129,
for major depressive disorder in		Z13.31, Z13.32, Z13.39,
adolescents aged 12 to 18 years.		Z13.41, or Z13.42
Screening should be implemented		
with adequate systems in place to		
ensure accurate diagnosis, effective treatment, and appropriate follow-		
up.		
- up.		
Refer also to Bright Futures 'Depression Screening' recommendation.		
Falls Prevention in Community	97110, 97112,	Procedure codes 97110,
Dwelling Older Adults:	97116, 97150,	97112, 97116, 97150, 97161,
Interventions	97161, 97162,	97162, 97163, 97164, 97165,
	97163, 97164,	97166, 97167, 97168, and
USPSTF "B" Recommendation April	97165, 97166,	97530 reimbursable with a
	97167, 97168,	diagnosis of Z91.81.
The USPSTF recommends exercise	97530	
interventions to prevent falls in		
community-dwelling adults aged 65		

years or older who are at increased risk for falls.		
Folic Acid for the Prevention of		For details about pharmacy
Neural Tube		benefit coverage, contact
Defects: Preventive Medication		the number on the patient's BCBS member card. A
USPSTF "A" Recommendation		patient's pharmacy benefit
January 2017		may be managed by a
The USPSTF recommends that all		company other than BCBS.
women who are planning or capable		
of pregnancy take a daily		Prescription required for
supplement containing 0.4 to 0.8 mg		both OTC and prescription
(400 to 800 µg) of folic acid.		medications.
Gestational Diabetes: Screening USPSTF "B" Recommendation August 2021 The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 weeks of gestation or after. Refer also to HRSA's 'Gestational Diabetes' recommendation	36415, 82947, 82948, 82950, 82951, 82952, 83036	Payable with a pregnancy diagnosis
Diabetes' <u>recommendation</u>		
Gonorrhea	87801, 87590,	Payable with a diagnosis
USPSTF "B" Recommendation September 2021 The USPSTF recommends screening for gonorrhea in sexually active women age 24 years and younger and in women 25 years or older who are at increased risk for infection.	87591, 87592, 87850	code in Diagnosis List 1

Healthy Diet and Physical Activity	99385, 99386,	
for Cardiovascular Disease	99387, 99395,	
Prevention in Adults with	99396, 99397,	
Cardiovascular Risk Factors:	G0438, G0439,	
Behavioral Counseling	G0446, S9452,	
	S9470, 97802,	
USPSTF "B" Recommendation	97803, 97804,	
November 2020	G0270, G0271,	
The USPSTF recommends offering or	99078, 99401,	
referring adults with cardiovascular	99402, 99403,	
disease risk factors to behavioral	99404, 99411,	
counseling interventions to promote	99412, G0473	
a healthy diet and physical activity.		
Healthy Weight and Weight Gain in	99384, 99385,	
Pregnancy: Behavioral Counseling	99386, 99394,	
Interventions	99395, 99396,	
	99401, 99402,	
USPSTF "B" Recommendation May	99403, 99404,	
2021	99411, 99412	
The USPSTF recommends that		
clinicians offer pregnant persons		
effective behavioral counseling		
interventions aimed at promoting		
healthy weight gain and preventing		
excess gestational weight gain in		
pregnancy.		
Hepatitis B in Pregnant Women	80055, 86704,	Payable with a pregnancy
Screening	86705, 86706,	diagnosis, or a diagnosis
	86707, 87340,	code in
USPSTF "A" Recommendation July	87341, 80074,	Diagnosis List 1
2019	80076,	
The USPSTF recommends screening	G0499, 36415	
for hepatitis B virus infection in		
pregnant women at their first		
prenatal visit.		

Hepatitis B Virus Infection	80055, 80074,	Payable with a diagnosis
Screening	80076, 86704,	code in
	86705, 86706,	Diagnosis List 1
USPSTF "B" Recommendation	86707, 87340,	
December 2020	87341	
The USPSTF recommends screening		
for hepatitis B virus infection in		
adolescents and adults at increased		
risk for infection.		
Hepatitis C Screening	86803, 86804,	Payable with a pregnancy
	87520, 87521	diagnosis, or a diagnosis
USPSTF "B" Recommendation March	G0472	code in Diagnosis List 1
2020		-
The USPSTF recommends screening		
for hepatitis C virus infection in		
adults aged 18 to 79 years.		
High Blood Pressure Screening in	93784, 93786,	Procedure codes 93784,
Adults	93788, 93790,	93786, 93788, 93790, 99473,
	99385, 99386,	and 99474 are reimbursable
USPSTF "A" Recommendation April	99387, 99395,	at the preventive level when
2021	99396, 99397,	billed with one of the
The USPSTF recommends screening	99473, 99474	following diagnosis codes:
for high blood pressure in adults		R03.0, R03.1, Z01.30, Z01.31
aged 18 years or older. The USPSTF		
recommends obtaining		
measurements outside of the clinical		
setting for diagnostic confirmation		
before starting treatment.		
Human Immunodeficiency Virus	HIV/Creatine	Consistent with <u>FAQs About</u>
(HIV)	Testing	Affordable Care Act
Infection Prevention Drug Pre-	82565, 82570,	Implementation Part 47,
exposure Prophylaxis (PrEP)	82575, 87534,	baseline and monitoring
	87535, 87536,	services related to PrEP
USPSTF "A" Recommendation June	87537, 87538,	medication are
2019 The USPETE recommends that	87539	reimbursable at the
The USPSTF recommends that		preventive level. See the
clinicians offer preexposure	Injection,	CPTs in the column to the
prophylaxis (PrEP) with effective	cabotegravir, 1mg,	

antiretroviral therapy to personsleft. Note: This list is notwho are at high risk of HIVHIV PrEP:exhaustive.	
Lwbo are at high rick of UIV LUIV DrED, Lovbauctive	
acquisition. See the ClinicalJ0739For details about benefit	
Considerations section for coverage, contact the	
information about identification of *87389, 87390, number on the patient's	
persons at high risk and selection of 87391, 87806, BCBS member card.	
effective antiretroviral therapy. G0432, G0433,	
G0435, 36415, For details about pharmacy	
USPSTF "A" Recommendation August86689, 86701,benefit coverage, contact	
2023 86702, 86703, the number on the patient'	5
The USPSTF recommends thatG0475, 80055,BCBS member card. A	
clinicians prescribe preexposure 80081, 86706, patient's pharmacy benefit	
prophylaxis using effective 87340, 87341, may be managed by a	
antiretroviral therapy to persons 80074, 80076, company other than BCBS.	
who are at increased risk of HIV G0499, 86803,	
acquisition to decrease the risk of 86804, G0472, Coverage includes generic	
acquiring HIV. Injectables are now 81025 Truvada (emtricitabine/	
added. tenofovir disoproxil	
*CPTs are not all fumarate) 200-300 mg	
specifically PrEP tablets, Apretude	
related and could (cabotegravir) 600 mg/ 3 m	_
be covered under intramuscular extended-	
other USPSTF, release suspension, and	
HRSA, and Bright Descovy (emtricitabine-	
Futurestenofovir alafenamide	
recommendations fumarate) 200-25 mg table	S
when used for prevention	
with a prescription. Refer to)
the member's drug list for	
coverage details.	
Diagnosis Codes HIV	
Related:	
Z11.4, Z71.7, B20, Z29.81	

Human Immunodeficiency Virus (HIV)Infection Screening for Non- Pregnant Adolescents and AdultsUSPSTF "A" Recommendation June 2019The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk should also be screened.Refer also to HRSA's 'HIV Screening and Counseling' recommendationRefer also to Bright Future's 'STI/HIV Screening' recommendation	87389, 87390, 87391, 87806, G0432, G0433, G0435	Payable with a diagnosis code in Diagnosis List 1
Human Immunodeficiency Virus(HIV)Infection Screening for PregnantWomenUSPSTF "A" Recommendation June2019The USPSTF recommends thatclinicians screen all pregnantpersons, , including those whopresent in labor or at delivery whoseHIV status is unknown.Refer also to HRSA's 'HIV Screening andCounseling' recommendationRefer also to Bright Future's 'STI/HIVScreening' recommendation	36415, 80081, 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87806, G0432, G0433, G0435, G0475	Payable with a pregnancy diagnosis or a diagnosis code in Diagnosis List 1

Hyportoncion in Adulta Carooning	02701 02706	Procedure codes 02794
Hypertension in Adults: Screening	93784, 93786,	Procedure codes 93784,
	93788, 93790,	93786, 93788, 93790, 99473,
USPSTF "A" Recommendation April	99385, 99386,	99474 are payable at no
2021	99387, 99395,	member cost share when
The U.S. Preventive Task Force	99396, 99397,	billed with the DX codes
(USPSTF) recommends screening for	99473, 99474	R03.0, R03.1, Z01.30, Z01.31
hypertension in adults 18 years or		
older with office blood pressure		
measurements (OBPM). The USPSTF		
recommends obtaining blood		
pressure measurements outside of		
the clinical setting for diagnostic		
confirmation before starting		
treatment.		
Intimate Partner Violence, Elder	99202, 99203,	Payable with a diagnosis
Abuse, and Abuse of Vulnerable	99204, 99205,	code in Diagnosis List 1
Adults Screening	99211, 99212,	
	99213, 99214,	
USPSTF "B" Recommendation	99215, 99384,	
October 2018	99385,	
The U.S. Preventive Services Task	99386,99387,	
Force (USPSTF) recommends that	99394, 99395,	
clinicians screen for intimate partner	99396, 99397,	
violence in women of reproductive	99401, 99402,	
age and provide or refer women who	99403, 99404,	
screen positive to ongoing support	99411, 99412,	
services.	99417, S0610,	
	S0612, S0613	
Latent Tuberculosis Infection	86480, 86481,	Payable with a diagnosis
Screening	86580	code in Diagnosis List 1
		_
USPSTF "B" Recommendation		
September 2016		
The USPSTF recommends screening		
for latent tuberculosis infection		
(LTBI) in populations at increased		
risk.		
risk.		

Lung Cancer Screening	G0296, 71271	Subject to medical policy
		criteria
USPSTF "B" Recommendation March		and may require
2021		preauthorization
The USPSTF recommends annual		
screening for lung cancer with low-		Eff. 01/01/2021 procedure
dose computed tomography (LDCT)		code 71271 is reimbursable
in adults aged 50 to 80 years who		at the preventive level if it
have a 20 pack-year smoking history		meets medical policy criteria
and currently smoke or have quit		and is billed with one of the
within the past 15 years. Screening		following
should be discontinued once a		diagnosis codes: F17.200,
person has not smoked for 15 years		F17.201, F17.210, F17.211,
or develops a health problem that		F17.220,
substantially limits life expectancy or		F17.221, F17.290, F17.291,
the ability or willingness to have		Z12.2, Z87.891
curative lung surgery.		
Weight Loss to Prevent Obesity-	97802, 97803,	
Related Morbidity and Mortality in	97804, 99385,	
Adults:	99386, 99387,	
Behavioral Interventions	99395, 99396,	
	99397, 99401,	
USPSTF "B" Recommendation	99402, 99403,	
September 2018	99404, 99411,	
The USPSTF recommends that	99412, 99078,	
clinicians offer or refer adults with a	G0447, G0473	
body mass index (BMI) of 30 or		
higher (calculated as weight in		
kilograms divided by height in		
meters squared) to intensive,		
multicomponent behavioral		
interventions.		

Obesity in Children and	97802, 97803,	
Adolescents	99383, 99384,	
Screening	99385, 99393,	
	99401, 99402,	
USPSTF "B" Recommendation June	99403, 99404,	
2017	99411, 99412,	
The USPSTF recommends that	G0446, G0447,	
clinicians screen for obesity in	G0473	
children and adolescents 6 years and		
older and offer them or refer them		
to comprehensive, intensive		
behavioral interventions to promote		
improvement in weight status.		
Ocular Prophylaxis for Gonococcal		When billed under inpatient
Ophthalmia Neonatorum		medical
Preventive Medication		
USPSTF "A" Recommendation		
January 2019		
The USPSTF recommends		
prophylactic ocular topical		
medication for all newborns to		
prevent gonococcal ophthalmia		
neonatorum.		
Osteoporosis Screening	76977, 77078,	Payable with a diagnosis
	77080, 77081,	code in Diagnosis List 1
USPSTF "B" Recommendation June	78350, 78351,	
	G0130	
The USPSTF recommends screening		
for osteoporosis with bone		
measurement testing to prevent osteoporotic fractures in women 65		
years and older.		
The USPSTF recommends screening		
for osteoporosis with bone		
measurement testing to prevent		
osteoporotic fractures in		

postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.		
Perinatal Depression: Preventive	99385,99386,	Payable with a diagnosis
Interventions	99387,	code in Diagnosis List 1
	99395, 99396,	
USPSTF "B" Recommendation	99397, 99401,	
February 2019	99402, 99403,	
The USPSTF recommends that	99404, 96160,	
clinicians provide or refer pregnant	96161,	
and postpartum persons who are at	G0444	
increased risk of perinatal		
depression to counseling		
interventions.		
Phenylketonuria in Newborns	84030, 99381,	Procedure codes 84030 and
Screening	S3620	S3620 reimbursable at the
		preventive level for children
USPSTF "A" Recommendation March		0-90 days old
2008		
The USPSTF recommends screening		
for phenylketonuria in newborns.		
Prediabetes and Type 2 Diabetes	82947, 82948,	Payable with a diagnosis
Screening	82950, 82951,	code in Diagnosis List 1
	83036, 82952,	
USPSTF "B" Recommendation August	97802, 97803,	
	97804, 99401,	
The USPSTF recommends screening	99402, 99403,	
for prediabetes and type 2 diabetes in adults aged 35 to 70 years who	99404, G0270,	
in adults aged 55 to 70 years with		

have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.	G0271, G0447, G0473, S9470	
Preeclampsia Screening		Preeclampsia screening is done through routine blood
USPSTF "B" Recommendation April 2017		pressure measurements
The USPSTF recommends screening		
for preeclampsia in pregnant women		
with blood pressure measurements		
throughout pregnancy.	00055 00050	
Rh(D) Incompatibility Screening	80055, 86850,	Payable with a pregnancy
USPSTF "A" Recommendation	86870, 86900, 86901, 36415	diagnosis
February 2004	00001, 00010	
The USPSTF strongly recommends		
Rh(D) blood typing and antibody		
testing for all pregnant women		
during their first visit for pregnancy-		
related care.		
USPSTF "B" Recommendation		
February 2004		
The USPSTF recommends repeated		
Rh(D) antibody testing for all		
unsensitized Rh(D)negative women		
at 24 to 28 weeks' gestation, unless		
the biological father is known to be		
Rh(D)-negative.		

Sexually Transmitted Infections	99384, 99385,	
Behavioral	99386, 99387,	
Counseling	99394, 99395,	
counsening	99396, 99397,	
USPSTF "B" Recommendation August	99401, 99402,	
2020	99403, 99404,	
The USPSTF recommends behavioral	99411, 99412,	
counseling for all sexually active	G0445	
adolescents and for adults who are		
at increased risk for sexually		
transmitted infections (STIs).		
Refer also to HRSA's 'Sexually		
Transmitted Infections Counseling'		
recommendation.		
Sickle Cell Disease	83020, 83021,	
(Hemoglobinopathies) in	83030, 83033,	
Newborns Screening	83051, 85004,	
	85013, 85014,	
USPSTF "A" Recommendation	85018, 85025,	
September 2007	85027, 99381,	
The USPSTF recommends screening	G0306, G0307,	
for sickle cell disease in newborns.	S3620, S3850	
Skin Cancer Counseling	There are no	
	procedure codes	
USPSTF "B" Recommendation March	specific to skin	
2018	cancer counseling.	
The USPSTF recommends counseling		
young adults, adolescents, children,		
and parents of young children about		
minimizing exposure to ultraviolet		
(UV) radiation for persons aged 6		
months to 24 years with fair skin		
types to reduce their risk of skin		
cancer.		

Statin Use for the Primary80061, 82465,For details about pharmacyPrevention of Cardiovascular83700, 83718,benefit coverage, contactDisease in Adults Preventive83719, 83721,the number on the patient'sMedication84478BCBS member card. AuSPSTF "B" Recommendation Augustatorwastatin for theprimary prevention of CVD for adultsatorwastatin 10 mg, 20 mg,aged 40 to 75 years who have 1 or40 mg, and 80 mg, lovastatinmore CVD risk factors (i.e.20 mg and 40 mg tablets,dyslipidemia, diabetes, hypertension,pravastatin 10 mg, 20 mg, 40or smoking) and an estimated 10-members ages 40 - 75 yearsof age with a prescription.86592, 86780,Syphilis Infection in Nonpregnant86592, 86780,Adults and0065UAdolescents Screening0065UUSPSTF "A" Recommendation June2016The USPSTF recommends screening
Disease in Adults Preventive Medication83719, 83721, 84478the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.USPSTF "B" Recommendation August 2022Coverage includes atorvastatin 10 mg,20 mg, 40 mg, and 80 mg, lovastatin 20 mg and 40 mg tablets, pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 - 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1
Medication84478BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.2022The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10- year risk of a cardiovascular event of 10% or greater.Coverage includes atorvastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets, for members ages 40 – 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1
USPSTF "B" Recommendation August 2022patient's pharmacy benefit may be managed by a company other than BCBS.The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10- year risk of a cardiovascular event of 10% or greater.Coverage includes atorvastatin 10 mg,20 mg, 40 mg, and 80 mg tablets, for members ages 40 - 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1
USPSTF "B" Recommendation August 2022may be managed by a company other than BCBS.The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10- year risk of a cardiovascular event of 10% or greater.Coverage includes atorvastatin 10 mg,20 mg, 40 mg, and 80 mg, lovastatin 20 mg and 40 mg tablets, pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 - 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screeningUSPSTF recommends screeningHouse and a screening
2022company other than BCBS.The USPSTF recommends thatCoverage includesclinicians prescribe a statin for thecoverage includesprimary prevention of CVD for adultsatorvastatin 10 mg,20 mg,aged 40 to 75 years who have 1 or40 mg, and 80 mg, lovastatinmore CVD risk factors (i.e.20 mg and 40 mg tablets,dyslipidemia, diabetes, hypertension,pravastatin 10 mg, 20 mg, 40or smoking) and an estimated 10-mg, and 80 mg tablets foryear risk of a cardiovascular event ofmembers ages 40 - 75 years10% or greater.86592, 86780,Syphilis Infection in Nonpregnant86592, 86780,Adults and0065UAdolescents Screening0065UUSPSTF "A" Recommendation June2016The USPSTF recommends screening
The USPSTF recommends thatCoverage includesclinicians prescribe a statin for theCoverage includesprimary prevention of CVD for adultsatorvastatin 10 mg,20 mg,aged 40 to 75 years who have 1 or40 mg, and 80 mg, lovastatinmore CVD risk factors (i.e.20 mg and 40 mg tablets,dyslipidemia, diabetes, hypertension,pravastatin 10 mg, 20 mg, 40or smoking) and an estimated 10-mg, and 80 mg tablets foryear risk of a cardiovascular event ofmembers ages 40 - 75 years10% or greater.of age with a prescription.Syphilis Infection in Nonpregnant86592, 86780,Adults and0065UAdolescents Screening0065UUSPSTF "A" Recommendation June2016The USPSTF recommends screening
clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10- year risk of a cardiovascular event of 10% or greater.Coverage includes atorvastatin 10 mg, 20 mg, 40 mg, and 80 mg, lovastatin 20 mg and 40 mg tablets, pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 – 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1
primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10- year risk of a cardiovascular event of 10% or greater.atorvastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets, pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 - 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screeningNonpregnant adults and adults adults
aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10- year risk of a cardiovascular event of 10% or greater.40 mg, and 80 mg, lovastatin 20 mg and 40 mg tablets, pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 - 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screeningUSPSTF recommends screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1
more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10- year risk of a cardiovascular event of 10% or greater.20 mg and 40 mg tablets, pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 – 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screeningImage: ScreeningImage: Screening
dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10- year risk of a cardiovascular event of 10% or greater.pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 – 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screeningImage: Commendation June Commends screeningImage: Commendation June Commends screeningImage: Commendation June Commends screening
or smoking) and an estimated 10- year risk of a cardiovascular event of 10% or greater. B6592, 86780, Adults and Adolescents Screening USPSTF "A" Recommendation June 2016 The USPSTF recommends screening
year risk of a cardiovascular event of 10% or greater.members ages 40 - 75 years of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screeningImage: ScreeningImage: Screening
10% or greater.of age with a prescription.Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screeningImage: ScreeningImage: Screening
Syphilis Infection in Nonpregnant Adults and Adolescents Screening86592, 86780, 0065UPayable with a diagnosis code in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screeningPayable with a diagnosis code in Diagnosis List 1
Adults and Adolescents Screening0065Ucode in Diagnosis List 1USPSTF "A" Recommendation June 2016 The USPSTF recommends screeningImage: Code in Diagnosis List 1
Adolescents Screening USPSTF "A" Recommendation June 2016 The USPSTF recommends screening
USPSTF "A" Recommendation June 2016 The USPSTF recommends screening
2016 The USPSTF recommends screening
2016 The USPSTF recommends screening
The USPSTF recommends screening
5
for syphilis infection in persons who
are at increased risk for infection.
Syphilis Infection in Pregnant80055, 80081,Payable with a pregnancy
Women86592, 86593,diagnosis or a diagnosis
Screening 86780, 0065U, code in Diagnosis List 1
36415
USPSTF "A" Recommendation
September 2018
The USPSTF recommends early
screening for syphilis infection in all
pregnant women.

Tobacco Smoking Cessation in	99401, 99402,	For details about pharmacy
Adults, Including Pregnant	99403, 99404,	benefit coverage, contact
Women: Behavioral and	99406, 99407,	the number on the patient's
Pharmacotherapy Interventions	G9016, S9453	BCBS member card. A
		patient's pharmacy benefit
USPSTF "A" Recommendation		may be managed by a
January 2021		company other than BCBS.
The USPSTF recommends that		
clinicians ask all adults about		Two 90-day treatment
tobacco use, advise them to stop		regimens per benefit period.
using tobacco, and provide		The 90-day treatments are
behavioral interventions and U.S.		at the discretion of the
Food and Drug Administration (FDA)-		provider working with the
approved pharmacotherapy for		member.
cessation to adults who use tobacco.		
		Prescription required for
USPSTF "A" Recommendation		both OTC and prescription
January 2021		medications.
The USPSTF recommends that		
clinicians ask all pregnant women		Coverage includes:
about tobacco use, advise them to		Generic bupropion hcl
stop using tobacco, and provide		(smoking deterrent) ER 12hr
behavioral interventions for		150 mg tablets
cessation to pregnant women who		• Generic nicotine polacrilex
use tobacco.		2 mg and 4 mg gum
		• Generic nicotine polacrilex
		2 mg and 4 mg lozenges
		• Generic nicotine 24hr 7
		mg, 14 mg, and 21 mg
		transdermal patches
		Generic varenicline tartrate
		0.5 mg and 1 mg tablets
		Brand Nicotine
		Transdermal Systems
		Brand Nicotrol Inhaler
		Brand Nicotrol Nasal Spray

Tobacco Use in Children and	99401, 99402,	Refer to Preventive Services
Adolescents	99403, 99404,	Recommendation for
Primary Care Interventions	99406, 99407,	Tobacco Smoking Cessation
	G9016, S9453	in Adults, Including Pregnant
USPSTF "B" Recommendation April		Women: Behavioral and
2020		Pharmacotherapy
The USPSTF recommends that		Interventions
primary care clinicians provide		
interventions, including education or		
brief counseling, to prevent initiation		
of tobacco use among school-aged		
children and adolescents.		
Screening for Unhealthy Drug Use	99385, 99386,	Payable with a diagnosis
	99387, 99395,	code in Diagnosis List 1
USPSTF "B" Recommendation June	99396, 99397,	
2020	99408, 99409,	
The USPSTF recommends screening	G0396, G0397	
by asking questions about unhealthy		
drug use in adults age 18 years or		
older. Screening should be		
implemented when services for accurate diagnosis, effective		
treatment, and appropriate care can		
be offered or referred.		
Vision Screening in Children	99172, 99173,	
	0333T	
USPSTF "B" Recommendation		
September 2017		
The USPSTF recommends vision		
screening at least once in all children		
aged 3 to 5 years to detect		
amblyopia or its risk factors.		
General Lab Panel	80050, 80053	Payable with a diagnosis
		code in Diagnosis List 1
These lab codes could be multiple		
Preventive Services		
recommendations.		

HRSA Recommendations:		
Service:	Procedure Code(s):	Additional Reimbursement Criteria:
Anxiety Screening	96127, 99384, 99385, 99386,	Procedure code 96127 is only reimbursable at the
HRSA Recommendation December 2019	99387, 99394, 99395, 99396,	preventive level when billed with a diagnosis of Z00.129,
The Women's Preventive Services Initiative recommends screening for anxiety in adolescent and adult	99397, G0444	Z13.31, Z13.32, Z13.39, Z13.41, or Z13.42
women, including those who are pregnant or postpartum.		
Breast Cancer Screening for Women at Average Risk	77061, 77062, 77063, 77065, 77066, 77067,	Payable with a diagnosis code in Diagnosis List 1
HRSA Recommendation December 2019	G0279	
The Women's Preventive Services Initiative recommends that average-		
risk women initiate mammography screening no earlier than age 40 and no later than age 50. Screening		
mammography should occur at least biennially and as frequently as		
annually. Screening should continue through at least age 74 and age alone should not be the basis to		
discontinue screening. These screening recommendations are for		
women at average risk of breast cancer. Women at increased risk		
should also undergo periodic mammography screening, however,		
recommendations for additional services are beyond the scope of this		
recommendation		

Refer also to USPSTF's 'Breast Cancer Screening' recommendation.		
Breastfeeding Services and Supplies HRSA Recommendation December	E0602, E0603, E0604, A4281, A4282, A4283, A4284, A4285,	Electric breast pumps limited to one per benefit period. Hospital Grade breast pumps are limited to
<u>2021</u> Women's Preventive Services Initiative recommends comprehensive lactation support	A4286, A4287, G0513, G0514, S9443, 99401, 99402, 99403,	rental only. G0513 & G0514 are payable with a diagnosis code in
services (including consultation; counseling; education by clinicians and peer support services; and breastfeeding equipment and supplies) during the antenatal,	99404, 99411, 99412, 99347, 99348, 99349, 99350, 98960, 98961,	Diagnosis List 1 Additional reimbursement information available within the
perinatal, and postpartum periods to optimize the successful initiation and maintenance of breastfeeding.	98962	"Breastfeeding Equipment and Supplies" Coverage
Breastfeeding equipment and supplies include, but are not limited to, double electric breast pumps (including pump parts and maintenance) and breast milk storage supplies. Access to double electric pumps should be a priority to optimize breastfeeding and should not be predicated on prior		Non-physician provider types such as Certified Lactation Counselors and International Board-Certified Lactation Consultants will only be eligible for reimbursement for the following codes: S9443, 98960, 98961, 98962.
failure of a manual pump. Breastfeeding equipment may also include equipment and supplies as clinically indicated to support dyads with breastfeeding difficulties and those who need additional services.		56500, 56501, 56502.

0096U, 0500T,	Payable with a diagnosis
87623, 87624,	code in Diagnosis List 1
87625, 88141,	
88142, 88143,	
88147, 88148,	
88150, 88152,	
88153, 88155,	
88164, 88165,	
88166, 88167,	
88174, 88175,	
99385, 99386,	
99387, 99395,	
99396, 99397,	
G0101, G0123,	
G0124, G0141,	
G0143, G0144,	
G0145, G0147,	
G0148, G0476,	
P3000, P3001,	
Q0091, S0610,	
S0612	
	37623, 87624, 37625, 88141, 38142, 88143, 38142, 88143, 38147, 88148, 38150, 88152, 38153, 88155, 38164, 88165, 38166, 88167, 38174, 88175, 9385, 99386, 9385, 99395, 9396, 99397, 50101, G0123, 50124, G0141, 50143, G0144, 50145, G0147, 50148, G0476, 23000, P3001, 20091, S0610,

Contraceptive Methods and	57170, 58300,	Contraception methods that
Counseling	58301, 58600,	require a prescription may
	58605, 58611,	be covered under the
HRSA Recommendation December	58615, 58661,	patient's medical or
2021	58565, 58670,	pharmacy benefit. For
Women's Preventive Services	58671, 58340,	details about pharmacy
Initiative recommends that	58700, 74740,	benefit coverage for
adolescent and adult women have	88302, 88305,	contraception, contact the
access to the full range of	96372, 11976,	number on the patient's
contraceptives and contraceptive	11981, 11982,	BCBS member card. A
care to prevent unintended	11983, A4261,	patient's pharmacy benefit
pregnancies and improve birth	A4264, A4266,	may be managed by a
outcomes. Contraceptive care	A4268, A4269,	company other than BCBS.
includes screening, education,	A9293, J1050,	
counseling, and provision of	J7296, J7297,	Visits pertaining to
contraceptives (including in the	J7298, J7300,	contraceptive counseling,
immediate postpartum period).	J7301, J7303,	initiation of contraceptive
Contraceptive	J7304, J7306,	use, and follow-up care may
care also includes follow-up care	J7307, A4267,	also apply to procedure
(e.g., management, evaluation and	S4981, S4989	codes under HRSA's 'Well-
changes, including the removal,		Woman'
continuation, and discontinuation of contraceptives).		recommendation
		Procedure code 58340
Women's Preventive Services		reimbursable at the
Initiative recommends that the full		preventive level only when
range of U.S. Food and Drug		accompanied with modifier
Administration (FDA)- approved,		33 or one of the following
granted, or -cleared contraceptives,		diagnosis codes: Z30.2,
effective family planning practices,		Z30.40, Z30.42, Z30.49,
and sterilization procedures be		Z98.51,
available as part of contraceptive		
care.		Procedure codes 11981,
		11982, and 11983 (are
The full range of contraceptives		covered only when FDA
includes those currently listed in the		approved contraceptive
FDA's Birth Control Guide: (1)		implant insertion or removal
sterilization surgery for women, (2)		are performed) are

implantable rods, (3) copper	reimbursable at the
intrauterine devices, (4) intrauterine	preventive level when
devices with progestin (all durations	
and doses), (5) injectable	
contraceptives, (6) oral	
contraceptives (combined pill), (7)	
oral contraceptives (progestin only),	

(8) oral contraceptives (extended or continuous use), (9) the contraceptive patch, (10) vaginal contraceptive rings, (11) diaphragms, (12) contraceptive sponges, (13) cervical caps, (14) condoms, (15) spermicides, (16) emergency contraception (levonorgestrel), and (17) emergency contraception (ulipristal acetate), and any additional contraceptives approved, granted, or cleared by the FDA. Additionally, instruction in fertility awareness-based methods, including the lactation amenorrhea method, although less effective, should be provided for women desiring an alternative method. condoms, (15) spermicides, (16) emergency contraception (levonorgestrel), and (17) emergency contraception (ulipristal acetate), and any additional contraceptives approved, granted, or cleared by the FDA. Additionally, instruction in fertility awareness-based methods, including the lactation amenorrhea method, although less effective, should be provided for women desiring an alternative method.

billed with one of the following diagnosis codes: Z30.013, Z30.017, Z30.018, Z30.019, Z30.09, Z30.40, Z30.42, Z30.46, Z30.49, Z30.8, Z30.9 Procedure codes 58661, 58700 reimbursable at the preventive level with a diagnosis of Z30.2

For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.

Prescription required for both OTC and prescription medications. For the list of contraceptive methods that may be covered, visit your health plan website.

Procedure code 96372 payable with a diagnosis code in Diagnosis list 1

Diabetes Screening after	82947, 82948,	Payable with a diagnosis
Pregnancy	82950, 82951,	code in Diagnosis List 1
	83036	
HRSA Recommendation December		
<u>2019</u>		
The Women's Preventive Services		
Initiative recommends women with a		
history of gestational diabetes		
mellitus (GDM) who are not currently		
pregnant and who have not been		
previously diagnosed with type 2		
diabetes mellitus should be screened		
for diabetes mellitus. Initial testing		
should ideally occur within the first		
year postpartum and can be		
conducted as early as 4–6 weeks		
postpartum. Women with a negative		
initial postpartum screening test		
result should be rescreened at least		
every 3 years for a minimum of 10		
years after pregnancy. For women		
with a positive postpartum screening		
test result, testing to confirm the		
diagnosis of diabetes is indicated		
regardless of the initial test (e.g., oral		
glucose tolerance test, fasting		
plasma glucose, or hemoglobin A1c).		
Repeat testing is indicated in women		
who were screened with hemoglobin		
A1c in the first 6 months postpartum		
regardless of the result.		

Gestational Diabetes	82947, 82948,	Payable with a pregnancy
	82950, 82951,	diagnosis
HRSA Recommendation December	83036	
2019		
The Women's Preventive Services		
Initiative recommends screening		
pregnant women for gestational		
diabetes mellitus after 24 weeks of		
gestation (preferably between 24		
and 28 weeks of gestation) in order		
to prevent adverse birth outcomes.		
Screening with a 50 g oral glucose		
challenge test (followed by a 3hour		
100 g oral glucose tolerance test if		
results on the initial oral glucose		
challenge test are abnormal) is		
preferred because of its high		
sensitivity and specificity. The		
Women's Preventive Services		
Initiative suggests that women with		
risk factors for diabetes mellitus be		
screened for preexisting diabetes		
before 24 weeks of gestation—		
ideally at the first prenatal visit,		
based on current clinical best		
practices.		
Refer also to USPSTF's 'Gestational		
Diabetes		
Mellitus Screening' recommendation.		

Counseling & Screening86701, 86702, 86703, 87389, 87390, 87391, 87390, 87391, 8730, 60433, G0435, G0475diagnosis List 1Initative recommends all adolescent and continuing as determined by risk.A screening text for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.86701, 86702, 8600, 843, 60435, 60455, 60455, 60455, 6045	Human Immune-Deficiency Virus	36415, 86689,	Payable when billed with a
86703, 87389, 87390, 87391, 87806, G0432, G0433, G0435, Initiative recommends all adolescent and adult women, ages 15 and older, receive a screening test for HIV at least once during their lifetime. Earlier or additional screening should be based on risk, and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection.Diagnosis List 1Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk.Diagnosis List 1A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.Bif To adolescent and adult women women upon initiation of vertical transmission.Bif To adolescent and adult women women upon initiation of vertical transmission.	-		5
HRSA Recommendation December 202187390, 87391, 87806, G0432, G0433, G0435, G0433, G0435, G0475Initiative recommends all adolescent and adult women, ages 15 and older, receive a screening test for HIV at least once during their lifetime. Earlier or additional screening should be based on risk, and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection.G0475Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk.HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.87390, 87391, 87391, 8730, 87391, 8730, 87391,	courseinig & screening		Ŭ
202187806, G0432,Women's Preventive ServicesG0433, G0435,Initiative recommends all adolescentG0475and adult women, ages 15 and older,G0475receive a screening test for HIV atIeast once during their lifetime.Earlier or additional screeningshould be based on risk, andrescreening annually or more oftenmay be appropriate beginning at age13 for adolescent and adult womenwith an increased risk of HIVinfection.Women's Preventive ServicesInitiative recommends riskassessment and preventioneducation for HIV infection beginningat age 13 and continuing asdetermined by risk.A screening test for HIV isrecommended for all pregnantwomen upon initiation of prenatalcare with rescreening duringpregnancy based on risk factors.Rapid HIV testing is recommendedfor pregnant women who present inactive labor with an undocumentedHIV status. Screening duringpregnancy enables prevention ofvertical transmission.	HPSA Pacammandation December		
Women's Preventive ServicesG0433, G0435,Initiative recommends all adolescentG0475and adult women, ages 15 and older,receive a screening test for HIV atleast once during their lifetime.Earlier or additional screeningShould be based on risk, andrescreening annually or more oftenmay be appropriate beginning at age13 for adolescent and adult womenwith an increased risk of HIVinfection.Women's Preventive ServicesInitiative recommends riskassessment and preventioneducation for HIV infection beginning at determined by risk.A screening test for HIV isrecommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors.Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
Initiative recommends all adolescent and adult women, ages 15 and older, receive a screening test for HIV at least once during their lifetime. Earlier or additional screening should be based on risk, and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
and adult women, ages 15 and older, receive a screening test for HIV at least once during their lifetime. Earlier or additional screening should be based on risk, and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
receive a screening test for HIV at least once during their lifetime. Earlier or additional screening should be based on risk, and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.		G0475	
least once during their lifetime. Earlier or additional screening should be based on risk, and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
Earlier or additional screening should be based on risk, and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.	0		
should be based on risk, and rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.	-		
rescreening annually or more often may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.	_		
may be appropriate beginning at age 13 for adolescent and adult women with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
13 for adolescent and adult women with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
 with an increased risk of HIV infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission. 			
infection. Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
Women's Preventive Services Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.	infection.		
Initiative recommends risk assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
assessment and prevention education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
education for HIV infection beginning at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
at age 13 and continuing as determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
determined by risk. A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
A screening test for HIV is recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.	determined by risk.		
recommended for all pregnant women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.	A screening test for LUV is		
women upon initiation of prenatal care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.	-		
care with rescreening during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.			
HIV status. Screening during pregnancy enables prevention of vertical transmission.	1 0 1		
pregnancy enables prevention of vertical transmission.			
vertical transmission.			
Refer also to USPSTF's 'Human			
	Refer also to USPSTF's 'Human		

Immunodeficiency Virus (HIV) Infection Screening for Pregnant and Non- Pregnant Adolescents and Adults' recommendation. Refer also to Bright Future's 'STI/HIV' Screening' recommendations.		
Interpersonal and Domestic	99401, 99402,	Payable when billed with a
Violence Screening	99403, 99404,	diagnosis code on Diagnosis
	99411, 99412,	List 1
HRSA Recommendation December	99384, 99385,	
2019	99386, 99387,	
The Women's Preventive Services	99394, 99395,	
Initiative recommends screening	99396, 99397,	
adolescents and women for	99202, 99203,	
interpersonal and domestic violence	99204, 99205,	
at least annually, and, when needed,	99211, 99212,	
providing or referring for initial	99213, 99214,	
intervention services. Interpersonal	99215, 99417	
and domestic violence includes		
physical violence, sexual violence,		
stalking and psychological		
aggression (including coercion),		
reproductive coercion, neglect, and		
the threat of violence, abuse, or		
both. Intervention services include,		
but are not limited to, counseling,		
education, harm reduction		
strategies, and referral to		
appropriate supportive services.		

Obesity Prevention in Midlife	97802, 97803,	Payable when billed with a
Women	97804, 99078,	diagnosis code in on
	99386, 99396,	Diagnosis List 1
HRSA Recommendation December	99401, 99402,	
2021	99403, 99404,	
Women's Preventive Services	99411, 99412,	
Initiative recommends counseling	G0447, G0473	
midlife women aged 40 to 60 years		
with normal or overweight body		
mass index (BMI) (18.5-29.9 kg/m2)		
to maintain weight or limit weight		
gain to prevent obesity. Counseling		
may include individualized		
discussion of healthy eating and		
physical activity.		
Sexually Transmitted Infections	99401, 99402, 99403,	
Counseling	99404, 99411,	
	99412, 99384, 99385, 99386,	
HRSA Recommendation December	99387, 99394,	
2021	99395, 99396,	
Women's Preventive Services	99397, G0445	
Initiative recommends directed		
behavioral counseling by a health		
care clinician or other appropriately		
trained individual for sexually active adolescent and adult women at an		
increased risk for STIs.		
Women's Preventive Services		
Initiative recommends that clinicians		
review a woman's sexual history and		
risk factors to help identify those at		
an increased risk of STIs. Risk factors		
include, but are not limited to, age		
younger than 25, a recent history of		
an STI, a new sex partner, multiple		
partners, a partner with concurrent		
partners, a partner with an STI, and a		

F	l	
lack of or inconsistent condom use.		
For adolescents and women not		
identified as high risk, counseling to		
reduce the risk of STIs should be		
considered, as determined by clinical		
judgment.		
Refer also to USPSTF's 'Sexually		
Transmitted Infections Behavioral		
Counseling' recommendation.		

Urinary Incontinence Screening	There are no	Payable with a diagnosis
	procedure codes	code in Diagnosis List 1
HRSA Recommendation December	specific to this	
2019	service. This	
The Women's Preventive Services	service would be	
Initiative recommends screening	part of the	
women for urinary incontinence	preventive office	
annually. Screening should ideally	visit.	
assess whether women experience		
urinary incontinence and whether it		
impacts		
their activities and quality of life. The		
Women's Preventive Services		
Initiative recommends referring		
women for further evaluation and		
treatment if indicated. The Women's		
Preventive Services Initiative		
recommends screening women for		
urinary incontinence as a preventive		
service. Factors associated with an		
increased risk for urinary		
incontinence include increasing		
parity, advancing age, and obesity;		
however, these factors should not be		
used to limit screening.		
Several screening tools demonstrate		
fair to high accuracy in identifying		
urinary incontinence in women.		
Although minimum screening		
intervals are unknown, given the		
prevalence of urinary incontinence,		
the fact that many women do not		
volunteer symptoms, and the		
multiple, frequently changing risk		
factors associated with incontinence,		
it is reasonable to conduct annually.		

Well-Woman Visits	99384, 99385,	Labs administered as part of
	99386, 99387,	a normal pregnancy
HRSA Recommendation December	99394, 99395,	reimbursable at the
2021	99396, 99397,	preventive level when billed
Women's Preventive Services	G0101, G0438,	with a pregnancy diagnosis
Initiative recommends that women	G0439, 99078,	
receive at least one preventive care	99401, 99402,	
visit per year beginning in	99403, 99404,	
adolescence and continuing across	99411, 99412,	
the lifespan to ensure the provision	99408, 99409,	
of all recommended preventive	G0396, G0442,	
services, including preconception	G0443, G0444	
and many services necessary for		
prenatal and interconception care,		
are obtained. The primary purpose		
of these visits should be the delivery		
and coordination of recommended		
preventive services as determined by		
age and risk factors. These services		
may be completed at a single or as		
part of a series of visits that take		
place over time to obtain all		
necessary services depending on a		
woman's age, health status,		
reproductive health needs,		
pregnancy status, and risk factors.		
Well-women visits also include pre-		
pregnancy, prenatal, postpartum		
and interpregnancy visits.		
ACIP Recommendations:		
Service:	Procedure	Additional Reimbursement
	Code(s):	Criteria:
COVID-19 Vaccine	After 11/01/2023:	
	91318, 91319,	
	1	

(MMR)		
Measles, Rubella, Congenital Rubella Syndrome, and Mumps	90707	
Maaalaa Duballa Canaanital	Q2038, Q2039	
	Q2036, Q2037,	
	Q2034, Q2035,	
	90694, 90756	
	90688, 90689,	
	90686, 90687,	
	90682, 90685,	
	90673, 90674,	
	90668, 90672,	
	90666, 90667,	
	90661,90662,	
	90658, 90660,	
	90656, 90657,	
	90654, 90655,	
Influenza Vaccine	90630, 90653,	
Human Papillomavirus Vaccine (HPV)	וכסטפ	Payable with a diagnosis code in Diagnosis List 1
(Hib) Vaccine	90651	Davable with a diagnosis
Haemophilus Influenzae Type B	90647, 90648	
	000017 000010	an in-network provider
		in the inpatient setting from
	90748, 90759	days of age when obtained
	90746, 90747,	level for newborns under 90
	90743, 90744,	payable at the preventive
Hepatitis B Vaccine	90739, 90740,	Hepatitis B Vaccination is
	90634, 90636	
Hepatitis A Vaccine	90632, 90633,	
	90723	
	90700, 90702,	
DTaP Vaccine	90696, 90698,	
	91322, 91304	
	91320, 91321,	

	Code(s):	Criteria:
Service:	Procedure	Additional Reimbursement
Bright Futures Recommendations:		
	50500, 50501	
	96380, 96381	
	90749, 90480,	
	90471, 90472, 90474,	
	90460, 90461, 90472,	
Immunization Administration	90460, 90461,	
Zoster (Shingles) Vaccine	90750	
Varicella Vaccine	90716	
Pertussis Vaccine (Tdap/Td)		
Diphtheria Toxoid and Acellular		
Tetanus Toxoid, Reduced	90714, 90715	
Rotavirus Vaccine	90680, 90681	
	90683	
Immunization	90679, 90678,	
Respiratory Syncytial Virus	90380, 90381,	
Polio Vaccine	90713	
	90684	
	90732, 90671,	
Pneumococcal Vaccine	90670, 90677,	
Monkeypox Vaccine	90611	
	90623	
	90620, 90621,	
-	90734, 90619,	
Meningococcal Vaccine	90644, 90733,	
Varicella (MMRV)		
Measles, Mumps, Rubella, and	90710	

Alcohol Use and Drug Use Assessment Bright Futures Recommends alcohol and drug use assessments for adolescents between the ages of 11 to 21 years.	99408, 99409	Payable with a diagnosis code in Diagnosis List 1
Anemia Screening in Children Bright Futures Recommends anemia screening for children under the age of 21 years of age.	85014, 85018	Payable with a diagnosis code in Diagnosis List 1 For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS. Prescription required for both OTC and prescription medications. Coverage provided for members up to 1 year of age.
Cervical Dysplasia Screening Bright Futures Recommends cervical dysplasia screening for adolescents age 21 years of age Critical Congenital Heart Defect Screening Bright Futures Recommends screening for critical congenital heart disease using pulse oximetry for newborns after 24	Q0091 94760	Payable with a diagnosis code in Diagnosis List 1

hours of age, before discharge from the hospital		
Depression Screening Bright Futures Recommends depression screening for adolescents between the ages of 11 to 21 years Refer also to USPSTF's 'Depression in Children and Adolescents Screening' recommendation	96127	Payable with a diagnosis code in Diagnosis List 1
Developmental Screening / Autism Screening Bright Futures Recommends developmental/autism screening for infants and young children between the ages of 9 months and 30 months	96110	Payable with a diagnosis code in Diagnosis List 1
Dyslipidemia Screening Bright Futures Recommends dyslipidemia screening for children and adolescents between the ages of 24 months and 21 years of age	80061, 82465, 83718, 84478	Payable with a diagnosis code in Diagnosis List 1

Hearing Screening Bright Futures	92558, 92567, 92551, 92650, 92651, 92652,	Procedure codes 92558, 92567, 92551, V5008 are payable at the preventive
Recommends hearing screenings for children and adolescents from birth through 21 years of age	92653, V5008	level only when billed with diagnosis codes Z01.10, Z01.118, and Z01.110 for ages 22 and under. Eff. 01/01/2021 CPT codes
		92650, 92651, 92652, 92653 may be payable at the preventive level only when billed with diagnosis codes Z01.10, Z01.118, and Z01.11 through ages 22 and under if meeting Medical Policy criteria.
Hematocrit or Hemoglobin	36415, 36416,	Payable with a diagnosis
Bright Futures Recommends hematocrit or hemoglobin screening for children and adolescents between the ages of four months and 21 years of age	85014, 85018	code in Diagnosis List 1
HIV Screening	87389, 87390, 87391, 87806, G0432, G0433, G0435	Payable with a diagnosis code in Diagnosis List 1
Lead Screening Bright Futures Recommends screening children between the ages of six months and six years for lead	36415, 36416, 83655	Payable with a diagnosis code in Diagnosis List 1

Maternal Depression Screening	99384, 99385,	
	99386, 99387,	
	99394, 99395,	
	99396, 99397,	
	G0444	
Newborn Bilirubin	82247, 82248,	Payable with a diagnosis
	88720	code in Diagnosis List 1
Newborn Blood Screening	S3620	Payable with a diagnosis
		code in Diagnosis List 1
Oral Health	99211, 99212,	Payable with a diagnosis
	99188, 99381,	code in Diagnosis List 1
Bright Futures	99382, 99383,	5
Recommends oral health risk	99384	
assessments beginning at six months		
of age		
Prenatal Visit	99401, 99402,	Payable with a diagnosis
	99403, 99404	code in Diagnosis List 1
Preventive Medicine Services: New	99381, 99382,	Payable with a diagnosis
Patients	99383, 99384,	code in Diagnosis List 1
	99385	
Preventive Medicine Services:	99391, 99392,	Payable with a diagnosis
Established Patients	99393, 99394,	code in Diagnosis List 1
	99395	
STI/HIV Screening	86631, 86632,	Payable with a diagnosis
	86701, 86703,	code in Diagnosis List 1
Bright Futures	87081, 87110,	
Recommends screening for all	87210, 87270,	
sexually active patients	87320, 87490,	
	87491, 87590,	
Refer also to USPSTF's 'Human	87591, 87800,	
Immunodeficiency Virus (HIV) Infection	87801, 87810,	
Screening for Pregnant and Non-	87850, 36415	
Pregnant		
Adolescents and Adults'		
recommendations		
Defer also to HDSN's (Sourcelly)		
Refer also to HRSA's 'Sexually		

Transmitted Infections Counseling' recommendation		
Tuberculosis Testing Bright Futures Recommends tuberculosis testing if the risk assessment is positive	86580, 99211	Payable with a diagnosis code in Diagnosis List 1
Vision Screening Bright Futures Recommends vision screening for newborns through age 21 years	99173	Payable with a diagnosis code in Diagnosis List 1

Many of the services listed above may be performed for indications other than preventive care. In these situations, services may be covered by another provision of the individual's benefit plan and subject to applicable cost sharing.

Z00.00	Z00.01	Z00.110	Z00.111	Z00.121	Z00.129	Z00.8	
Z01.411	Z01.419	Z02.83	Z11.1	Z11.3	Z11.4	Z11.51	
Z11.7	Z12.11	Z12.12	Z12.2	Z12.31	Z12.39	Z12.4	
Z12.5	Z13.0	Z13.1	Z13.220	Z13.31	Z13.32	Z13.40	
Z13.41	Z13.42	Z13.5	Z13.6	Z13.820	Z20.2	Z20.6	
Z23	Z30.011	Z30.012	Z30.013	Z30.014	Z30.015	Z30.016	
Z30.017	Z30.018	Z30.019	Z30.02	Z30.09	Z30.40	Z30.41	
Z30.42	Z30.430	Z30.431	Z30.432	Z30.433	Z30.44	Z30.45	
Z30.46	Z30.49	Z30.8	Z30.9	Z32.2	Z71.41	Z71.51	
Z71.6	Z71.7	Z71.82	Z71.83	Z86.32	Z97.5	R73.03	

Diagnosis List 1

Breastfeeding Equipment & Supplies

Non-grandfathered plans provide coverage of manual, electric, and hospital grade breast pumps along with breastfeeding supplies at the preventive level.

Manual breast pumps utilize procedure code E0602 and are available for purchase and covered at the preventive level when obtained In-Network, Out of Network, or from Retail providers. Sales tax is excluded from retail purchases.

Electric breast pumps utilize procedure code E0603 and must be rented or purchased from an InNetwork provider or a contracted durable medical equipment supplier. The models of breast pumps being provided at the preventive level are up to the individual provider's discretion. If a member chooses to obtain an upgraded model, they may be balance billed the difference between the allowance of the standard model and the cost of the upgraded model. Members are allowed one electric breast pump per benefit period.

*Note: Retail providers such as Target, Wal-Mart, or online vendor are not licensed medical providers and therefore are considered Out of Network. Out of network coverage will follow the out of network benefit level for preventive services. This may include cost sharing and sales tax is excluded. *

Hospital grade breast pumps utilize procedure code E0604 and are only covered when rented InNetwork or from an In-Network durable medical equipment supplier. Hospital grade breast pump coverage is up to the purchase price of \$1,000.00 or 12 months, whichever comes first. At the end of coverage, the unit must be returned to the durable medical equipment supplier. Members are allowed one breast pump per benefit period.

Breast pumps obtained from Out of Network providers are reimbursable at the Out of Network level.

The following breast pump supplies are reimbursable at the preventive level. Some limitations and restrictions may apply based on the group coverage for preventive services.

- A4281- Tubing for breast pump, replacement, spare membranes, replacements
- A4282- Adapter for breast pump, replacement
- A4283- Cap for breast pump bottle, replacement
- A4284- Breast shield and splash protector for use with breast pump, replacement
- A4285- Polycarbonate bottle for use with breast pump, replacement
- A4286- Locking ring for breast pump, replacement

Differentiating Preventive Care versus Diagnostic Care

The following types of services are considered Preventive:

- Screenings intended to prevent illness or identify issues before symptoms are evident
- Counseling intervention as defined by a specific preventive recommendation

Examples of preventive services:

- A 60-year-old woman obtains her biennial mammogram to screen for breast cancer
- A patient who has been identified as having cardiovascular disease risk factors is referred for nutritional counseling
- A 50-year-old patient obtains a colonoscopy to screen for colorectal cancer
- A 42-year-old patient goes to their doctor for their annual physical and receives a blood test to screen for abnormal blood glucose

The following types of services are considered Diagnostic:

- The diagnosis of existing symptoms or abnormalities
- Treatment for specific health conditions, ongoing care, or other tests to manage a health condition

Examples of diagnostic services:

- A 60-year-old woman obtains a mammogram after noticing a lump in her breast
- A patient diagnosed with diabetes is referred for nutritional counseling to manage their condition
- A patient goes to their doctor for their annual physical and receives a blood test to check iron and liver function, and a urinalysis is requested

Limitations and Exclusions

- 1. <u>Services not reimbursable at the preventive level may be reimbursable under</u> <u>another portion of the medical plan.</u>
- 2. Breastfeeding equipment and supplies not listed underneath the "Breastfeeding Equipment and

Supplies" section. This includes, but is not limited to

- a. Batteries
- b. Breastfeeding ointments, creams
- c. Breast milk storage supplies including bags, freezer packs, etc.
- d. Breast pump cleaning supplies
- e. Breast pump traveling cases

- f. Infant scales
- g. Nursing bras
- h. Nursing covers, scarfs
- 3. Immunizations that are not published in the Center for Disease Control's Morbidity and Mortality Weekly Report (MMWR) and/or are not on the list of "Vaccines Licensed for Use in the United States" by the United States Food and Drug Administration (FDA).
- 4. Prescription coverage may vary depending on the terms and conditions of the plans. A prescription may be required for coverage under the pharmacy benefit. The plan may also require that the generic drug be tried first before the brand version. Age limits, restrictions, and other requirements may apply. Members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
- 5. For OTC purchases, members will need to obtain a prescription from their provider and take it to the pharmacy to be filled.
- 6. Exceptions may apply, members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
- 7. If there is a medication not included, the member should consult their doctor for therapeutic alternatives first before submitting coverage exceptions to BCBS.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a MEDICAL POLICY and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

References

Advisory Committee on Immunization Practices (ACIP). "Vaccine-Specific ACIP Recommendations."

Retrieved March 1, 2022, from https://www.cdc.gov/vaccines/hcp/acip-recs/index.html

American Academy of Pediatrics- Bright Futures. "Coding for Pediatric Preventive Care, 2022." Retrieved March 16, 2023, from https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf?_ga=2.94179101.1664058044. 1678994595-714521604.1673643544

American Academy of Pediatrics - Bright Futures. "Recommendations for Preventive Pediatric Health Care." Retrieved March 1, 2023, from <u>https://publications.aap.org/pediatrics/article/150/1/e2022058044/188302/2022-</u> <u>Recommendationshttps://publications.aap.org/pediatrics/article/150/1/e2022058044/188302/2022-</u> <u>Recommendations-for-Preventive-Pediatric?_ga=2.129116298.748527027.1677624224-</u> <u>1461735393.1677624222?autologincheck=redirectedfor-Preventive-</u> <u>Pediatric?_ga=2.129116298.748527027.1677624224-</u> <u>1461735393.1677624222?autologincheck=redirectedfor-Preventive-</u>

American Academy of Pediatrics- Bright Futures. "Achieving Bright Futures." Retrieved March 16, 2023, from <u>https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf?_ga=2.170328992.1664058044.1678994</u> 595-714521604.1673643544

Centers for Disease Control and Prevention. "Immunization Schedules." Retrieved March 1, 2022, from <u>https://www.cdc.gov/vaccines/schedules/index.html</u>

Health Resources and Services Administration. "Women's Preventive Services Guidelines." Retrieved December 15th, 2022, from <u>https://www.hrsa.gov/womens-guidelines</u>

United States Food and Drug Administration. "Vaccines Licensed for Use in the United States." Retrieved March 1, 2022, <u>https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833</u>

United States Preventive Services Task Force. "Published Recommendations." Retrieved March 1, 2022, from

https://www.uspreventiveservicestaskforce.org/BrowseRec/Index/browse-recommendations

Approval Date	Description
06/23/2017	New policy, replaces medical policy ADM1001.030
07/14/2017	Removed codes 99174 and 99177.
12/06/2017	Coding and USPSTF updates
04/30/2018	Coding and USPSTF updates

Policy Update History

07/12/2018	Coding and USPSTF updates
12/27/2018	Coding and USPSTF updates
09/26/2019	Coding and USPSTF updates
10/14/2019	HPV vaccine update
12/30/2019	Disclaimer, Coding and USPSTF updates
04/20/2020	Recommendation updates
06/08/2020	Disclaimer, Coding, Links, and recommendation updates
09/09/2020	Coding and recommendation updates
12/21/2020	Coding and recommendation updates, drug information updates and disclaimers
01/12/2021	Coding updates
09/22/2021	Coding and recommendation updates, drug information updates
12/16/2021	Coding and USPSTF updates
03/23/2022	Coding and recommendation updates
06/01/2022	Coding and recommendation updates
07/29/2022	Diagnosis List 1 updates
09/09/2022	Coding and recommendation updates
02/20/2023	Coding updates
03/16/2023	Coding and recommendation updates, hyperlink updates
5/24/2023	Coding and recommendation updates
06/01/2023	Coding and recommendation updates
09/25/2023	Coding and recommendation updates
09/27/2023	Coding and recommendation updates
12/18/2023	Coding and recommendation updates
3/22/2024	Coding and recommendation updates
06/01/2024	Coding and recommendation updates
08/29/2024	Coding and recommendation updates
02/01/2025	Verbiage updates for Prep

The Plan makes no endorsement, representations or warranties regarding any products or services offered by independent third-party vendors such as Target and Wal-Mart. These vendors are solely responsible for the products and services they offer. If you have any questions about the products or services offered by such vendors, you should contact the vendor(s) directly.